About us

Advicenne is a late-stage biopharmaceutical company focused on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications.

Our goal is to improve the lives of patients from early childhood through adulthood by leveraging our pharmaceutical and clinical development expertise to develop paediatric friendly therapeutics that answer critical unmet medical needs in the field of rare and neglected diseases.

The Company was established in 2007 in Nimes (France) and is listed on the regulated market of Euronext in Paris (ISIN: FR0013296746; Euronext ticker: ADVIC).